Heron Therapeutics Stock Price, News & Analysis (NASDAQ:HRTX) $1.44 -0.01 (-0.69%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$1.43▼$1.5250-Day Range$0.54▼$1.5052-Week Range$0.50▼$3.41Volume2.11 million shsAverage Volume2.35 million shsMarket Capitalization$216.11 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Heron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside386.1% Upside$7.00 Price TargetShort InterestBearish11.72% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$260,650 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.88) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector205th out of 955 stocksPharmaceutical Preparations Industry66th out of 400 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Heron Therapeutics has a forecasted upside of 386.1% from its current price of $1.44.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.72% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 2.5 News and Social Media Coverage News SentimentHeron Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 2 articles on an average week.Search Interest22 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat Follows9 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $260,650.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions81.77% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 13.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Heron Therapeutics Stock (NASDAQ:HRTX)Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Read More HRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRTX Stock News HeadlinesNovember 30, 2023 | seekingalpha.comWhy Heron Therapeutics Is A Compelling Buy Into 2024November 19, 2023 | finance.yahoo.comCEO & Director of Heron Therapeutics Craig Collard Buys 411% More SharesDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 17, 2023 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceNovember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Asensus Surgical (ASXC), Cue Health (HLTH) and Heron Therapeutics (HRTX)November 15, 2023 | markets.businessinsider.comWhy Is Pain Treatment Focused Heron Therapeutics Stock Trading Higher Today?November 15, 2023 | finance.yahoo.comQ3 2023 Heron Therapeutics Inc Earnings CallNovember 15, 2023 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call TranscriptDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024November 14, 2023 | finance.yahoo.comHeron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesNovember 14, 2023 | finance.yahoo.comHeron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceNovember 13, 2023 | markets.businessinsider.comHeron Therapeutics is about to announce its earnings — here's what to expectNovember 7, 2023 | finance.yahoo.comHeron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023October 29, 2023 | nypost.comPhilly motorcyclist filmed stomping on car windshield arrested after his employer tips off policeOctober 14, 2023 | thetimes.co.ukThe Boy and the Heron review — another Studio Ghibli masterpieceAugust 15, 2023 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatesAugust 15, 2023 | finance.yahoo.comQ2 2023 Heron Therapeutics Inc Earnings CallAugust 15, 2023 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call TranscriptAugust 15, 2023 | finance.yahoo.comHeron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to SayAugust 15, 2023 | finance.yahoo.comHeron Therapeutics, Inc.'s (NASDAQ:HRTX) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measuresAugust 14, 2023 | finance.yahoo.comHeron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatesAugust 8, 2023 | finance.yahoo.comHeron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023August 3, 2023 | msn.comHeron Therapeutics (HRTX) Price Target Decreased by 5.19% to 7.45July 28, 2023 | msn.comHeron Therapeutics: Restructuring Brings About A New DawnJuly 27, 2023 | benzinga.comDirector of Heron Therapeutics Makes $3.41M BuyJuly 24, 2023 | nasdaq.comHeron Therapeutics Announces Cost Reduction Plan - Quick FactsSee More Headlines Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/23/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees203Year Founded1983Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+386.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,020,000.00 Net Margins-97.45% Pretax Margin-97.45% Return on Equity-21,127.62% Return on Assets-53.07% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio1.91 Sales & Book Value Annual Sales$107.67 million Price / Sales2.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book13.09Miscellaneous Outstanding Shares150,070,000Free Float140,468,000Market Cap$216.10 million OptionableOptionable Beta1.51 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Craig Alexander Collard (Age 57)CEO & Director Ms. Ira Duarte (Age 54)Executive VP & CFO Ms. Lisa Peraza (Age 46)VP & Chief Accounting Officer Comp: $474.1kDr. Thomas B. Ottoboni Ph.D. (Age 64)Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences Mr. Ryan CraigVice President of MarketingMr. Sean T. Ristine (Age 53)Senior Vice President of Human Resources Dr. Chris M. Storgard (Age 57)Chief Medical Officer Mr. Robert Sullivan (Age 45)Senior VP of Oncology Care Franchise & Commercial Operations Dr. William P. Forbes Pharm. D. (Age 61)Pharm.D., Executive VP & Chief Development Officer Jeff CohnExecutive Director, Assistant General Counsel & Assistant SecretaryMore ExecutivesKey CompetitorsKamadaNASDAQ:KMDALifecore BiomedicalNASDAQ:LFCRRenovaro BiosciencesNASDAQ:RENBAEON BiopharmaNASDAQ:AEONInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsGraham Capital Management L.P.Sold 22,276 shares on 11/22/2023Ownership: 0.098%Craig A CollardBought 150,000 shares on 11/16/2023Total: $138,000.00 ($0.92/share)Ira DuarteBought 85,000 shares on 11/16/2023Total: $75,650.00 ($0.89/share)William P ForbesBought 50,000 shares on 11/16/2023Total: $47,000.00 ($0.94/share)Rubric Capital Management LPBought 14,963,503 shares on 11/15/2023Ownership: 18.978%View All Insider TransactionsView All Institutional Transactions HRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Heron Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks. What is Heron Therapeutics' stock price target for 2024? 3 brokers have issued 1-year target prices for Heron Therapeutics' shares. Their HRTX share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 386.1% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts. How have HRTX shares performed in 2023? Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX shares have decreased by 42.4% and is now trading at $1.44. View the best growth stocks for 2023 here. When is Heron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HRTX earnings forecast. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. The biotechnology company had revenue of $30 million for the quarter, compared to the consensus estimate of $27.24 million. Heron Therapeutics had a negative net margin of 97.45% and a negative trailing twelve-month return on equity of 21,127.62%. The company's revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) EPS. What ETFs hold Heron Therapeutics' stock? ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI). What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN). Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Rubric Capital Management LP (18.98%), JW Asset Management LLC (1.71%), Tejara Capital Ltd (1.50%), Tejara Capital Ltd (1.50%), Adage Capital Partners GP L.L.C. (1.42%) and New York State Common Retirement Fund (0.78%). Insiders that own company stock include Adam Morgan, Craig A Collard, Craig A Johnson, David Leslie Szekeres, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..Read More This page (NASDAQ:HRTX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.